Anebulo Pharmaceuticals Inc (ANEB)
1.46
-0.04
(-2.67%)
USD |
NASDAQ |
Nov 22, 16:00
1.59
+0.13
(+8.90%)
After-Hours: 20:00
Anebulo Pharmaceuticals Cash from Financing (Quarterly)
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | -0.0624M |
| September 30, 2023 | |
| June 30, 2023 | -0.0682M |
| March 31, 2023 | 0.00 |
| December 31, 2022 | -0.2489M |
| Date | Value |
|---|---|
| September 30, 2022 | 6.699M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 20.18M |
| March 31, 2021 | 1.656M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.2489M
Minimum
Dec 2022
20.18M
Maximum
Jun 2021
2.166M
Average
--
Median
Sep 2021
Cash from Financing (Quarterly) Benchmarks
| Revance Therapeutics Inc | -6.087M |
| NovaBay Pharmaceuticals Inc | 2.089M |
| Palatin Technologies Inc | -0.127M |
| iBio Inc | -0.162M |
| Theriva Biologics Inc | 3.716M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.69M |
| Free Cash Flow | -7.054M |
| Free Cash Flow Per Share (Quarterly) | -0.0652 |
| Free Cash Flow Yield | -18.66% |